The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
O'Brien, M. E. R., Ciuleanu, T.-E., Tsekov, H., Shparyk, Y., Čučeviá, B., Juhasz, G., Thatcher, N., Ross, G. A., Dane, G. C., & Crofts, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5821 · Cited by 649
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Severe acute interstitial pneumonia and gefitinib
Inoue, A., Saijo, Y., Maemondo, M., Gomi, K., Tokue, Y., Kimura, Y., Ebina, M., Kikuchi, T., Moriya, T., & Nukiwa, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12190-3 · Cited by 450
Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations
Rossi, S. E., Erasmus, J. J., McAdams, H. P., Sporn, T. A., & Goodman, P. C. (2000) · RadioGraphics · doi:10.1148/radiographics.20.5.g00se081245 · Cited by 449
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases
Abrey, L. E., Olson, J. D., Raizer, J. J., Mack, M., Rodavitch, A., Boutros, D. Y., & Malkin, M. G. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012226718323 · Cited by 230
KL-6: A Serum Marker for Interstitial Pneumonia
Kobayashi, J., & Kitamura, S. (1995) · Chest · doi:10.1378/chest.108.2.311 · Cited by 219
Pfisterer, J., Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J.-U., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj296 · Cited by 211
Impaired Lung Branching Morphogenesis in the Absence of Functional EGF Receptor
Miettinen, P. J., Warburton, D., Bu, D., Zhao, J.-S., Berger, J. E., Minoo, P., Koivisto, T., Allen, L., Dobbs, L., Werb, Z., et al. (1997) · Developmental Biology · doi:10.1006/dbio.1997.8593 · Cited by 190
Takano, T., Ohe, Y., Kusumoto, M., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Tamura, T., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.01.010 · Cited by 176
Interstitial lung disease associated with drug therapy
Camus, P., Kudoh, S., & Ebina, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602063 · Cited by 173
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
Durán, I., Siu, L. L., Oza, A. M., Chung, T., Sturgeon, J. F. G., Townsley, C. A., Pond, G. R., Seymour, L., & Niroumand, M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.015 · Cited by 152
Pulmonary toxicity from novel antineoplastic agents
Dimopoulou, I., Bamias, A., Lyberopoulos, P., & Dimopoulos, M. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj057 · Cited by 146
Circulating KL-6 levels in patients with drug induced pneumonitis
Ohnishi, H. (2003) · Thorax · doi:10.1136/thorax.58.10.872 · Cited by 144
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2
Clamon, G. H., Herndon, J. E., Kern, J. A., Govindan, R., Garst, J. L., Watson, D. M., & Green, M. (2005) · Cancer · doi:10.1002/cncr.20950 · Cited by 115
KL‐6 levels are elevated in plasma from patients with acute respiratory distress syndrome
Satō, H., Callister, M. E. J., Mumby, S. E., Quinlan, G. J., Welsh, K. I., du Bois, R. M., & Evans, T. W. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00070303 · Cited by 114
Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate
Ohnishi, K., Sakai, F., Kudoh, S., & Ohno, R. (2006) · Leukemia · doi:10.1038/sj.leu.2404207 · Cited by 104
Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms
Atabai, K., Ishigaki, M., Geiser, T., et al. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00396.2001 · Cited by 104
Gemcitabine‐induced severe pulmonary toxicity
Barlési, F., Villani, P., Doddoli, C., Gimenez, C., & Kleisbauer, J. P. (2004) · Fundamental and Clinical Pharmacology · doi:10.1046/j.0767-3981.2003.00206.x · Cited by 98
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
Kumar, S. K., Witzig, T. E., & Rajkumar, S. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.127 · Cited by 94
Kollmannsberger, C., Schittenhelm, M. M., Honecker, F. U., Tillner, J., Weber, D., Oechsle, K., Kanz, L., & Bokemeyer, C. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl042 · Cited by 94
Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy
Briasoulis, E. C., & Pavlidis, N. A. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2-153 · Cited by 94
A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy
Roychowdhury, D. F., Cassidy, C. A., Peterson, P. M., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1016214032272 · Cited by 92
Understanding the mechanisms of drug-associated interstitial lung disease
Higenbottam, T., Kuwano, K., Nemery, B., & Fujita, Y. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602065 · Cited by 81
Thalidomide-associated deep vein thrombosis and pulmonary embolism
Bennett, C. L., Schumock, G. T., Desai, A. A., Kwaan, H. C., Raisch, D. W., Newlin, R. C., & Stadler, W. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01300-1 · Cited by 81
Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?
Herbst, R. S., & Sandler, A. B. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-19 · Cited by 69
Pulmonary Infiltrates Following Administration of Paclitaxel
Ramanathan, R. K., Reddy, V. V., Holbert, J. M., & Belani, C. P. (1996) · CHEST Journal · doi:10.1378/chest.110.1.289 · Cited by 68
Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil???)
Skubitz, K. M., & Skubitz, A. P. N. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199801000-00005 · Cited by 65
Hypersensitivity Pneumonitis Related to Imatinib Mesylate
Bergeron, A., Bergot, E., Vilela, G. D. B., Adès, L., Devergié, A., Espérou, H., Socié, G., Calvo, F. M., Gluckman, É., Ribaud, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.99.179 · Cited by 64
Acute lung injury as a possible adverse drug reaction related to gefitinib
Ieki, R., Saitoh, E., & Shibuya, M. (2002) · European Respiratory Journal · doi:10.1183/09031936.03.00098503 · Cited by 50
Paclitaxel-Induced Hypersensitivity Pneumonitis: Radiographic and CT Findings
Wong, P., Leung, A. N. C., Berry, G. J., Atkins, K. A., Montoya, J. G., Ruoss, S. J., & Stockdale, F. E. (2001) · American Journal of Roentgenology · doi:10.2214/ajr.176.3.1760718 · Cited by 47
Irinotecan-associated pulmonary toxicity
Madarnas, Y., Webster, P. M., Shorter, A. M., & Bjarnason, G. A. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200010000-00007 · Cited by 43
Hypersensitivity reactions to teniposide (VM-26): an analysis.
O'Dwyer, P. J., King, S. A., Fortner, C. L., & Leyland-Jones, B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1262 · Cited by 41
Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature
Ostoros, G., Pretz, A., Fillinger, J., SOLTESZ, I., & Döme, B. (2006) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200602001-00071 · Cited by 37
Reichardt, P., Nielsen, O. S., Bauer, S., Hartmann, J. T., Schöffski, P., Christensen, T. B., Pink, D., Daugaard, S., Marreaud, S. I., Glabbeke, M. M. V., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.014 · Cited by 36
Roth, B. J., Manola, J. B., Dreicer, R., Graham, D. L., & Wilding, G. (2002) · Investigational New Drugs · doi:10.1023/a:1020675017737 · Cited by 33
Erlotinib‐Associated Acute Pneumonitis: Report of Two Cases
Vahid, B., & Esmaili, A. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/832605 · Cited by 25
Self-citationGrimison, P., Goldstein, D., Schneeweiss, J., & Murray, N. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2004.00757.x · Cited by 25
Brandwein, J. M., Yang, L., Schimmer, A. D., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404545 · Cited by 23
Chen, Y.-M. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00445-2 · Cited by 21
Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung.
Suzaki, N., Hiraki, A., Takigawa, N., Ueoka, H., Tanimoto, Y., Kozuki, T., Tabata, M., Kanehiro, A., Kiura, K., & Tanimoto, M. (2006) · PubMed · doi:10.18926/amo/30737 · Cited by 16
Maitland, M. L., Wilcox, R. L., Hogarth, D. K., Desai, A. A., Caligiuri, P., Abrahams, C., & Salgia, R. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.07.017 · Cited by 14
Cited by
Brunelli, A., Charloux, A., Bolliger, C. T., Rocco, G., Sculier, J.-P., Varela, G., Licker, M., Ferguson, M. K., Faivre-Finn, C., Huber, R. M., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00184308 · Cited by 955
Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
Matsuno, O. (2012) · Respiratory Research · doi:10.1186/1465-9921-13-39 · Cited by 319
Lustberg, M. B., Kuderer, N. M., Desai, A., Bergerot, C., & Lyman, G. H. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00776-9 · Cited by 306
Metadata
- Authors
- Vahid, B., & Marik, P. E.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 133
- Issue
- 2
- Pages
- 528-538
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2088817198
- Cited by
- 254
- References
- 50
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.